The contrasting mechanisms of serum resistance of Neisseria gonorrhoeae and group B Neisseria meningitidis. 1999

S Ram, and F G Mackinnon, and S Gulati, and D P McQuillen, and U Vogel, and M Frosch, and C Elkins, and H K Guttormsen, and L M Wetzler, and M Oppermann, and M K Pangburn, and P A Rice
The Maxwell Finland Laboratory for Infectious Diseases, Boston Medical Center, MA 02118, USA. sram@bu.edu

Neisseria gonorrhoeae and Neisseria meningitidis have evolved intricate mechanisms to evade complement-mediated killing. Sialylation of gonococcal lipooligosaccharide (LOS) results in conversion of previously serum sensitive strains to unstable serum resistance, which is mediated by factor H binding. Porin (Por) is also instrumental in mediating stable serum resistance in gonococci. The 5th loop of certain gonococcal PorlAs binds factor H, which efficiently inactivates C3b to iC3b. Factor H glycan residues may be essential for factor H binding to certain Por1A strains. Por1A strains can also regulate the classical pathway by binding to C4b-binding protein (C4bp) probably via the 1st loop of the Por molecule. Certain serum resistant Por1 B strains can also regulate complement by binding C4bp through a loop other than loop 1. Purified C4b can inhibit binding of C4bp to Por 1B, but not Por1A, suggesting different binding sites on C4bp for the two Por types. Unlike serum resistant gonococci, resistant meningococci have abundant C3b on their surface, which is only partially processed to iC3b. The main mechanism of complement evasion by group B meningococci is inhibition of membrane attack complex (MAC) insertion by their polysaccharide capsule. LOS structure may act in concert with capsule to prevent MAC insertion. Meningococcal strains with Class 3 Por preferentially bind factor H, suggesting Class 3 Por acts as a receptor for factor H.

UI MeSH Term Description Entries
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D009344 Neisseria gonorrhoeae A species of gram-negative, aerobic bacteria primarily found in purulent venereal discharges. It is the causative agent of GONORRHEA. Diplococcus gonorrhoeae,Gonococcus,Gonococcus neisseri,Merismopedia gonorrhoeae,Micrococcus der gonorrhoe,Micrococcus gonococcus,Micrococcus gonorrhoeae
D009345 Neisseria meningitidis A species of gram-negative, aerobic BACTERIA. It is a commensal and pathogen only of humans, and can be carried asymptomatically in the NASOPHARYNX. When found in cerebrospinal fluid it is the causative agent of cerebrospinal meningitis (MENINGITIS, MENINGOCOCCAL). It is also found in venereal discharges and blood. There are at least 13 serogroups based on antigenic differences in the capsular polysaccharides; the ones causing most meningitis infections being A, B, C, Y, and W-135. Each serogroup can be further classified by serotype, serosubtype, and immunotype. Diplokokkus intracellularis meningitidis,Meningococcus,Micrococcus intracellularis,Micrococcus meningitidis,Micrococcus meningitidis cerebrospinalis,Neisseria weichselbaumii
D001770 Blood Bactericidal Activity The natural bactericidal property of BLOOD due to normally occurring antibacterial substances such as beta lysin, leukin, etc. This activity needs to be distinguished from the bactericidal activity contained in a patient's serum as a result of antimicrobial therapy, which is measured by a SERUM BACTERICIDAL TEST. Activities, Blood Bactericidal,Activity, Blood Bactericidal,Bactericidal Activities, Blood,Bactericidal Activity, Blood,Blood Bactericidal Activities
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013045 Species Specificity The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species. Species Specificities,Specificities, Species,Specificity, Species
D018272 Porins Porins are protein molecules that were originally found in the outer membrane of GRAM-NEGATIVE BACTERIA and that form multi-meric channels for the passive DIFFUSION of WATER; IONS; or other small molecules. Porins are present in bacterial CELL WALLS, as well as in plant, fungal, mammalian and other vertebrate CELL MEMBRANES and MITOCHONDRIAL MEMBRANES. Pore Protein,Pore Proteins,Porin,Protein, Pore,Proteins, Pore
D066298 In Vitro Techniques Methods to study reactions or processes taking place in an artificial environment outside the living organism. In Vitro Test,In Vitro Testing,In Vitro Tests,In Vitro as Topic,In Vitro,In Vitro Technique,In Vitro Testings,Technique, In Vitro,Techniques, In Vitro,Test, In Vitro,Testing, In Vitro,Testings, In Vitro,Tests, In Vitro,Vitro Testing, In

Related Publications

S Ram, and F G Mackinnon, and S Gulati, and D P McQuillen, and U Vogel, and M Frosch, and C Elkins, and H K Guttormsen, and L M Wetzler, and M Oppermann, and M K Pangburn, and P A Rice
February 2011, Expert review of anti-infective therapy,
S Ram, and F G Mackinnon, and S Gulati, and D P McQuillen, and U Vogel, and M Frosch, and C Elkins, and H K Guttormsen, and L M Wetzler, and M Oppermann, and M K Pangburn, and P A Rice
January 1987, Antonie van Leeuwenhoek,
S Ram, and F G Mackinnon, and S Gulati, and D P McQuillen, and U Vogel, and M Frosch, and C Elkins, and H K Guttormsen, and L M Wetzler, and M Oppermann, and M K Pangburn, and P A Rice
September 2003, Frontiers in bioscience : a journal and virtual library,
S Ram, and F G Mackinnon, and S Gulati, and D P McQuillen, and U Vogel, and M Frosch, and C Elkins, and H K Guttormsen, and L M Wetzler, and M Oppermann, and M K Pangburn, and P A Rice
August 1987, Journal of clinical microbiology,
S Ram, and F G Mackinnon, and S Gulati, and D P McQuillen, and U Vogel, and M Frosch, and C Elkins, and H K Guttormsen, and L M Wetzler, and M Oppermann, and M K Pangburn, and P A Rice
February 2001, The Journal of antimicrobial chemotherapy,
S Ram, and F G Mackinnon, and S Gulati, and D P McQuillen, and U Vogel, and M Frosch, and C Elkins, and H K Guttormsen, and L M Wetzler, and M Oppermann, and M K Pangburn, and P A Rice
February 1978, Canadian Medical Association journal,
S Ram, and F G Mackinnon, and S Gulati, and D P McQuillen, and U Vogel, and M Frosch, and C Elkins, and H K Guttormsen, and L M Wetzler, and M Oppermann, and M K Pangburn, and P A Rice
January 2019, PeerJ,
S Ram, and F G Mackinnon, and S Gulati, and D P McQuillen, and U Vogel, and M Frosch, and C Elkins, and H K Guttormsen, and L M Wetzler, and M Oppermann, and M K Pangburn, and P A Rice
April 1984, Journal of clinical microbiology,
S Ram, and F G Mackinnon, and S Gulati, and D P McQuillen, and U Vogel, and M Frosch, and C Elkins, and H K Guttormsen, and L M Wetzler, and M Oppermann, and M K Pangburn, and P A Rice
April 1989, Clinical microbiology reviews,
S Ram, and F G Mackinnon, and S Gulati, and D P McQuillen, and U Vogel, and M Frosch, and C Elkins, and H K Guttormsen, and L M Wetzler, and M Oppermann, and M K Pangburn, and P A Rice
January 1988, Sexually transmitted diseases,
Copied contents to your clipboard!